Search results
Showing 1 to 12 of 12 results for psoriasis and biologics
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
View recommendations for CG153Show all sections
This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS40Show all sections
Sections for QS40
- Quality statements
- Quality statement 1: Assessing disease severity
- Quality statement 2: Assessing impact of disease
- Quality statement 3: Referring to specialist services
- Quality statement 4: Assessing cardiovascular risk
- Quality statement 5: Assessing for psoriatic arthritis
- Quality statement 6: Monitoring systemic therapy
- Update information
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Biographies and registered interests for members of the Technology Appraisal Committee A
Find out more about NICE technology appraisals advisory committee D members
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.